importance of tissue diagnosis and genetic analysis in the evaluation of LV wall thickening when conflicting clinical features suggest divergent diagnoses. In addition, clinicians should consider superimposition of AL amyloid cardiomyopathy in patient with rapid clinical deterioration.
Case Description
A 62-year-old woman with hypertension and newly diagnosed AL amyloidosis was initially referred to the Boston University/Boston Medical Center Amyloidosis Center in 2006 for evaluation of suspected amyloidosis and increased left ventricular wall thickness noted by echocardiogram. There was no significant family history of heart disease or sudden cardiac death. A bladder biopsy obtained during evaluation for persistent hematuria revealed extensive amyloid disposition. A bone marrow biopsy xsmarrow biopsy. This was accompanied by markedly elevated serum lambda free light chains and monoclonal lambda protein in urine and serum immuno fixation electrophoresis, confirming the diagnosis of systemic AL amyloidosis (Table 1) . Treatment with nine cycles of melphalan and dexamethasone resulted in a very good partial hematologic response with normaliza-Abstract A 62-year-old woman with newly diagnosed systemic AL amyloidosis was evaluated for severely increased left ventricular (LV) wall thickness. Her echocardiographic, cardiac MRI, and genetic findings led to a diagnosis of hypertrophic cardiomyopathy (HCM). Five years after achieving relative a partial hematologic response with chemotherapy, the patient died after developing rapidly progressive heart failure and cardiogenic shock. A full autopsy diagnosed both cardiac amyloidosis and HCM. The overlapping phenotypes of these two diseases resulted in a clinical diagnostic dilemma. This case highlights the importance of tissue diagnosis and genetic analysis in the evaluation of LV wall thickening when conflicting clinical features suggest divergent diagnoses.
Introduction
We present a case of increased left ventricular wall thickness in a patient with AL amyloidosis. The patient was ultimately diagnosed with both hypertrophic cardiomyopathy and AL cardiac amyloidosis. The overlapping phenotypes of these two diseases resulted in a clinical diagnostic dilemma. This case highlights the A B Note the prominent and asymmetric septal thickening consistent with HCM; B) Still frame late gadolinium enhancement (LGE) cardiac MRI short axis image slices from base to apex are illustrated. Note the focal late enhancement (single arrow) of the interventricular septum in a pattern consistent with HCM. Also note the poor contrast between myocardium and blood pool with subtle subdendocardial LGE (double arrow) that could also be consistent with cardiac amyloidosis.
1C). Further testing demonstrated a serum Brain Natriuretic Peptide of 1388 pg/mL (normal < 53.2 pg/ml). An electrocardiogram showed normal sinus rhythm, left ventricular hypertrophy, left anterior fascicular block, and ST-T waves changes consistent with repolarization abnormality (Figure 2 ). Cardiac MRI (CMR) revealed a septal thickness of 19 mm and left ventricular mass of 532 g, LVEF of 59%, right ventricular ejection fraction of 52%, and a single focus of delayed enhancement within the anterior wall in a pattern that did not suggest an infiltrative cardiomyopathy (Figure 3 and Video 2). These tion of serum free light concentration, but persistent monoclonal protein in serum and urine by immunofixation electrophoresis and 5-10% lambda-restricted plasma cells on subsequent bone marrow biopsies.
A screening transthoracic echo at presentation to our center showed a severely increased interventricular septal thickness of 22 mm, grade 1 diastolic dysfunction pattern, systolic anterior motion of the mitral valve with a left ventricular outflow gradient of 46 mmHg, mild mitral regurgitation, and left ventricular ejection fraction (LVEF) of 50% (Figure 1 , Video 1A, Video 1B and Video hypertrophy (10 mm) and increased ventricular septal thickness (maximum thickness 30 mm). There was extensive interstitial birefringent congophilic material in the left ventricle and interventricular septum, diagnostic of cardiac amyloidosis. The uninvolved myocardial fibers were hypertrophied with myocyte disarray, consistent with the diagnostic histological features of HCM (Figure 4 and Figure 5 ).
Conclusion
We present an unusual case of a woman with severely increased LV wall thickness and systemic AL amyloidosis who was ultimately diagnosed with both hypertrophic cardiomyopathy and AL cardiac amyloidosis at autopsy.
The systemic amyloidosis is a group of diseases caused by organ deposition of misfolded protein fragments. Disease manifestations and clinical course vary depending upon the precursor protein. In AL amyloido-CMR and echocardiographic findings confirmed a diagnosis of hypertrophic cardiomyopathy (HCM).
Blood testing for cardiac sarcomere mutations was sent and family members screened. There were no affected first-degree relatives, however the patient's genetic testing was significant for a missense mutation in MYH7, a β-myosin heavy chain gene, associated with HCM [1] .
Over a five-year period, the patient slowly started to develop signs and symptoms of congestive heart failure ( Table 2 ). The LVEF fluctuated, but largely remained preserved (Table 3 ). However, the septal wall thickness gradually began to increase and reached up to 29 mm.
Six years after her initial presentation, the patient was acutely hospitalized for decompensated heart failure and ultimately died of cardiogenic shock. A focused autopsy was performed, revealing cardiomegaly, left ventricular hypertrophy (990 grams), right ventricular cases of AL amyloidosis displaying echocardiographic findings typically associated with HCM, including LV outflow gradients and mitral systolic anterior motion [11] . There are few reports, of both HCM and amyloid cardiomyopathy occurring in the same patient [12] , and even fewer with histopathological confirmation. In a case series of septal myectomy for presumed HCM, three out of 204 patients were found to have amyloid deposits, and all were over the age of 60-years with wild-type ATTR as the precursor protein [13] .
On imaging, cardiac amyloidosis can be distinguished from HCM by traditional echo parameters, including more advanced LV diastolic dysfunction and low normal or impaired LV systolic function. There is considerable overlap in echocardiographic features, however, and these and other classic parameters lack sensitivity in distinguishing cardiac amyloidosis from HCM [14] . Recently, the inclusion of various cardiac deformation parameters increases the sensitivity and specificity for the detection of amyloidosis, especially the LVEF to global longitudinal strain ratio [14] . In addition, a non-invasive, diagnostic algorithm can accurately be used to diagnosis cardiac ATTR amyloidosis, even in cohorts with HCM [15] .
Our patient had markedly increased ventricular wall thickness consistent with either cardiac amyloidosis or HCM. The patient had autopsy-proven, extensive extracellular amyloid deposition in the heart in the setting of known AL amyloidosis, consistent with a diagnosis of cardiac amyloidosis [16] . In addition to her cardiac amyloidosis, she was genotype and phenotype positive for HCM. The preponderance of clinical evidence suggested concomitant HCM as well: Asymmetric septal hyper-sis, the amyloidogenic protein is derived from monoclonal immunoglobulin light chains in the setting of a plasma cell dyscrasia. The incidence of AL amyloidosis is estimated to be about 9 cases per million people per year [2, 3] . Tissue involvement with amyloid protein is diagnosed by light microscopy revealing characteristic apple-green birefringence with Congo red staining [4] . Cardiac involvement is common, affecting up to 50-70% of patients with systemic AL amyloidosis [5, 6] . In contrast to AL amyloidosis, transthyretin (ATTR) cardiac amyloidosis is a distinct cause of cardiac amyloidosis which may be slowly progressive (particularly wild-type ATTR), and most resembles HCM in its echocardiographic appearance.
Cardiac amyloidosis is characterized by increased LV wall thickness, diastolic dysfunction, and low voltages on ECG [7] . The disease course in untreated patients is often one of rapidly progressive heart failure due to the underlying restrictive cardiomyopathy [8] , often complicated by advanced conduction system disease and rarely, ventricular arrhythmias [9] .
Hypertrophic cardiomyopathy (HCM) is a genetic cardiomyopathy caused by autosomal dominant mutations in genes encoding for the sarcomere and its associated myofibrils, with a prevalence of about 1 in 500 people worldwide [10] . While HCM is defined as LV hypertrophy (typically with septal wall thickness > 15 mm), in the absence of other cardiac or systemic diseases leading to LV hypertrophy, overlap between HCM and other causes of LV hypertrophy has been well described. A prior report from our institution demonstrates the phenotypic overlap that can occur between cardiac amyloidosis and HCM, with four out of 97 new 
